Đánh giá nguy cơ huyết khối tĩnh mạch trên người bệnh u lympho mới chẩn đoán và điều trị hoá chất toàn thân dựa trên thang điểm Khorana=Risk of venous thrombosis based on the Khorana scale in newly diagnosed malignant lymphoma patients at K hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Huyền Nga Đỗ, Thanh Tùng Nguyễn, Thị Thu Hường Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.646-652

Bộ sưu tập: Metadata

ID: 478341

Thêm vào giỏ

Describe the risk of venous thromboembolism based on the Khorana score in patients with newly diagnosed malignant lymphoma and treated with systemic chemotherapy at the Hematologic Oncology Department - K Hospital in 2022. Subjects and methods: Cross-sectional prospective study to assess the risk of venous thromboembolism based on the Khorana score conducted on 157 newly diagnosed malignant lymphoma patients and treated with systemic chemotherapy at the Hematologic Oncology Department - K Hospital in 2022. Results: The average age of patients is 53.96 years old, Ps=0 accounts for 69.4%, the proportion of stage 2 patients accounts for 33.1%, The proportion of patients with extranodal lesions accounts for 40.1%, Most patients have a disease progression time of ≤ 2 months, the proportion of patients with Bulky tumors accounts for 21%. Base on Khorana scale, most of the patients in the study were at low risk, accounting for 68.2%
The proportion of patients at average risk is 24.2%
high risk 7.6%. The proportion of patients at high and intermediate risk gradually decreased after cycles of chemotherapy. Conclusion: The study results show that the Khorana score is suitable for clinical use in assessing patients' thrombosis risk and thromboprophylaxis for high-risk groups.Mô tả nguy cơ huyết khối tĩnh mạch dựa vào thang điểm Khorana trên bệnh nhân u lympho mới chẩn đoán và điều trị hoá chất toàn thân. Đối tượng và phương pháp: Nghiên cứu mô tả đánh giá nguy cơ huyết khối tĩnh mạch dựa vào thang điểm Khorana tiến hành trên 157 bệnh nhân u lympho ác tính mới được chẩn đoán và điều trị hoá chất toàn thân tại khoa nội hệ tạo huyết Bệnh viện K năm 2022. Kết quả: Độ tuổi trung bình của bệnh nhân là 53,96 tuổi, PS=0 chiếm đa số 69,4%, Tỉ lệ bệnh nhân giai đoạn 2 chiếm cao nhất 33,1%, Tỉ lệ bệnh nhân có tổn thương ngoài hạch chiếm 40,1%, đa số bệnh nhân có thời gian diễn biến bệnh ≤ 2 tháng, Tỉ lệ bệnh nhân có u lớn chiếm 21%. Theo điểm Khorana, hầu hết người bệnh có nguy cơ thấp chiếm 68,2%
nguy cơ trung bình chiếm 24,2%
nguy cơ cao 7,6%. Tỉ lệ bệnh nhân có nguy cơ cao và trung bình giảm dần sau các chu kì điều trị hóa chất. Kết luận: Thang điểm Khorana phù hợp sử dụng trên lâm sàng đánh giá nguy cơ huyết khối của bệnh nhân và dự phòng huyết khối cho nhóm đối tượng nguy cơ cao.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR